Edesa Biotech (EDSA): CEO received 5,714 shares
Pardeep Nijhawan, CEO at Edesa Biotech, reported a grant / award of 5,714 shares.
- 5,714
- Shares
- Traded
- Sep 1, 2026
- Filed
- Sep 2, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 13, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 19, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
What came next
- Oct 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 23, 2026, the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board, approved increases in the annual base salaries of Dr. Pardeep Nijhawan, the Company’s Chief Executive Officer, from $357,696 to $657,423, Dr. Michael Brooks, the Company’s President, from $335,340 to $591,681, and Peter Weiler, the Company’s Chief…”
- Nov 4, 20265% stakeMillennium Management LLC reported a passive stake (13G) of 8.7%
- Nov 8, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
- Nov 12, 20265% stakeAdage Capital Management, L.P. reported a passive stake (13G) of 7.8%
- Nov 16, 20265% stakeSirenia Capital Management LP reported a passive stake (13G) of 9.9%
- Nov 16, 20265% stakeStemPoint Capital LP reported a passive stake (13G) of 9.9%
- Nov 16, 20265% stakeRubric Capital Management LP reported a passive stake (13G) of 4.6%
- Nov 16, 20265% stakeBoxer Capital Management, LLC reported a passive stake (13G) of 6.9%
- Nov 16, 20265% stakePerceptive Advisors LLC reported a passive stake (13G) of 4.2%
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Edesa Biotech
For Edesa Biotech, OQRO holds 5 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EDSA page.
Other recent filings by Pardeep Nijhawan, Chief Executive Officer
- SEC Form 4 at Edesa Biotech (EDSA)Mar 11, 2026
- SEC Form 4 at Edesa Biotech (EDSA)Mar 7, 2026
- SEC Form 4 at Edesa Biotech (EDSA)Mar 6, 2026
- SEC Form 4 at Edesa Biotech (EDSA)Mar 5, 2026
- SEC Form 4 at Edesa Biotech (EDSA)Mar 4, 2026
The full history of Pardeep Nijhawan, Chief Executive Officer is on the profile page.
How this filing works
Explore the data
Common questions
Which Edesa Biotech (EDSA) insider traded, and how much?
Pardeep Nijhawan, CEO at Edesa Biotech, reported a grant / award of 5,714 shares. Not an open-market trade.
When did it happen, and when was it made public?
Traded: Sep 1, 2026. Filed: Sep 2, 2026. That is 1 day between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Edesa Biotech recently?
For Edesa Biotech, OQRO holds 5 fund holdings reports (13F) dated in the last 90 days. They are listed on the EDSA page.
Does this mean EDSA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Edesa Biotech
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 12, 2026
- SEC Form 4Mar 12, 2026
Everything OQRO holds on this company is on its EDSA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
